MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
Old Articles: <Older 7561-7570 Newer>
The Motley Fool
June 21, 2011
Brian Orelli
Data Look Good, Approval Unknown Accelerated approvals are like that. The data should give Curis' investors added confidence that vismodegib works, but whether it can get approved with this limited data remains to be seen. mark for My Articles 169 similar articles
The Motley Fool
June 21, 2011
Alexander Crawford
Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list? mark for My Articles 726 similar articles
The Motley Fool
June 21, 2011
Frank Vinluan
GSK HIV Drug Pipeline Sees Boost as Partner Concert Steers to Clinical Trials GSK and Concert have a possible new treatment for HIV. mark for My Articles 128 similar articles
The Motley Fool
June 20, 2011
Cindy Johnson
11 Health-Care Stocks Insiders Are Buying What the insiders are doing can tell us a lot. mark for My Articles 188 similar articles
The Motley Fool
June 20, 2011
Travis Hoium
Gentiva Health Services Shares Plunged: What You Need to Know Shares of home-health service provider Gentiva Health Services caught a cold and fell 10% today after an analyst downgrade. mark for My Articles 11 similar articles
The Motley Fool
June 20, 2011
Brian Orelli
Pfizer's Pain-Free FDA Approval. More to Come? Oxecta gains FDA approval. Remoxy is up next. mark for My Articles 160 similar articles
The Motley Fool
June 20, 2011
Brian Orelli
See Drug, Approve Drug An approval of Regeneron's macular degeneration Eylea looks likely. mark for My Articles 503 similar articles
The Motley Fool
June 20, 2011
Seth Jayson
A Hidden Reason Why the Future Looks Bright for Omnicell Although Omnicell shows inventory growth that outpaces revenue growth, the company may also display positive inventory divergence, suggesting that management sees increased demand on the horizon. mark for My Articles 618 similar articles
The Motley Fool
June 20, 2011
Luke Timmerman
Pfizer's Idea to Fix the Drug Development Crisis, Which Probably Won't Work (But Just Might) In a worst-case scenario, Pfizer flushes a few hundred million dollars down the tubes. What's the best-case scenario? mark for My Articles 360 similar articles
The Motley Fool
June 17, 2011
Brian Orelli
Pick Your Poison: Lung Cancer or Heart Attack How much will the FDA's new warning affect Pfizer's Chantix? mark for My Articles 94 similar articles
<Older 7561-7570 Newer>    Return to current articles.